Exemestane - Latest Advances

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Journal: eLife

Published: July 28, 2025

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: July 20, 2025

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab.

Journal: Current oncology (Toronto, Ont.)

Published: June 30, 2025

Exploring the efficacy and mechanisms of exemestane-loaded nanoparticles in targeted breast cancer therapy.

Journal: Biomaterials advances

Published: June 30, 2025

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning.

Journal: Medicina (Kaunas, Lithuania)

Published: June 22, 2025

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: May 30, 2025

Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: a case report and literature review.

Journal: Frontiers in oncology

Published: May 29, 2025

Molecular Docking, Dynamics, and Cytotoxicity Assessment of Pyrazolo[1,5-a]pyrimidine Derivatives Against Breast Cancer.

Journal: Chemistry & biodiversity

Published: May 27, 2025

Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 20, 2025

Exemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway.

Journal: Fish physiology and biochemistry

Published: May 04, 2025

Medication-Related Osteonecrosis of the Jaw induced by a CDK 4/6 inhibitor (Palbociclib) in a patient who was naïve to Antiresorptive Bone Therapy: A Case Report.

Journal: Oral surgery, oral medicine, oral pathology and oral radiology

Published: April 30, 2025

Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.

Journal: Breast cancer research and treatment

Published: March 25, 2025

Filters

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy.

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy.

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab.

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab.

Exploring the efficacy and mechanisms of exemestane-loaded nanoparticles in targeted breast cancer therapy.

Exploring the efficacy and mechanisms of exemestane-loaded nanoparticles in targeted breast cancer therapy.

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning.

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning.

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.

Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: a case report and literature review.

Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: a case report and literature review.

Molecular Docking, Dynamics, and Cytotoxicity Assessment of Pyrazolo[1,5-a]pyrimidine Derivatives Against Breast Cancer.

Molecular Docking, Dynamics, and Cytotoxicity Assessment of Pyrazolo[1,5-a]pyrimidine Derivatives Against Breast Cancer.

Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer.

Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer.

Exemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway.

Exemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway.

Medication-Related Osteonecrosis of the Jaw induced by a CDK 4/6 inhibitor (Palbociclib) in a patient who was naïve to Antiresorptive Bone Therapy: A Case Report.

Medication-Related Osteonecrosis of the Jaw induced by a CDK 4/6 inhibitor (Palbociclib) in a patient who was naïve to Antiresorptive Bone Therapy: A Case Report.

Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.

Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.